ACE Report Cover
Efficacy and Safety of an Etofenamate Medicated Plaster for Acute Ankle Sprain
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
FOOT & ANKLE
Efficacy and Safety of an Etofenamate Medicated Plaster for Acute Ankle Sprain .
Verified
This report has been verified by one or more authors of the original publication.

Efficacy and Safety of an Etofenamate Medicated Plaster for Acute Ankle Sprain: A Randomized Controlled Trial.

Orthop J Sports Med. 2021 Aug 12;9(8): 23259671211032591.

One hundred and fifty-six patients with unilateral, acute, uncomplicated lateral ankle sprains were randomized to receive 7 days of etofenamate plaster use (n=78) or a placebo plaster (n=78) for pain relief. The primary outcome of interest was the change from baseline in Visual Analog Scale (VAS) pain on movement scores at 72 hours. Additionally, pain scores during rest and movement, time to response, and adverse events were recorded over the 7 day treatment period. Results revealed significantly greater pain relief, both at rest and during movement, in the etofenamate group compared to placebo throughout the 7 day treatment period. In the etofenamate group, the time to a meaningful and optimal response was shorter than placebo. 3 adverse events were observed in the placebo group vs. 2 adverse events in the etofenamate group, all of mild/moderate intensity.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Efficacy and Safety of an Etofenamate Medicated Plaster for Acute Ankle Sprain. ACE Report. 2021;94(1):2. Available from: https://myorthoevidence.com/AceReport/Show/efficacy-and-safety-of-an-etofenamate-medicated-plaster-for-acute-ankle-sprain

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report